Edition:
United States

Chromadex Corp (CDXC.OQ)

CDXC.OQ on NASDAQ Stock Exchange Capital Market

5.32USD
23 Feb 2018
Change (% chg)

$0.06 (+1.14%)
Prev Close
$5.26
Open
$5.28
Day's High
$5.34
Day's Low
$5.09
Volume
56,074
Avg. Vol
110,821
52-wk High
$7.24
52-wk Low
$2.26

Select another date:

Fri, Feb 16 2018

BRIEF-Chromadex Chairman Stephen Allen Will Retire From The Board

* CHROMADEX CHAIRMAN STEPHEN ALLEN WILL RETIRE FROM BOARD OF DIRECTORS

BRIEF-ChromaDex Corp Sees Q4 2017 Revenue About $7.5 Mln

* AN OPERATING LOSS FOR Q4 OF 2017 IS EXPECTED TO BE IN A RANGE OF $8.5 MILLION TO $9.5 MILLION

BRIEF-Chromadex - Patent Trial And Appeal Board Of U.S. Patent And Trademark Office Denied Elysium Health's Request To Invalidate U.S. Patent

* CHROMADEX - PATENT TRIAL AND APPEAL BOARD OF U.S. PATENT AND TRADEMARK OFFICE DENIED ELYSIUM HEALTH INC.'S REQUEST TO INVALIDATE U.S. PATENT

BRIEF-ChromaDex And Watsons Expand Partnership With Tru Niagen Retail Launch In Singapore

* CHROMADEX AND WATSONS EXPAND PARTNERSHIP WITH TRU NIAGEN™ RETAIL LAUNCH IN SINGAPORE Source text for Eikon: Further company coverage:

BRIEF-Chromadex Files For Resale Of Up To 5.6 Mln Shares Of Common Stock By The Selling Stockholders

* CHROMADEX CORP FILES FOR RESALE OF UP TO 5.6 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: [http://bit.ly/2kt48c4] Further company coverage:

BRIEF-ChromaDex Corp qtrly ‍reported net sales of $6.1 million from continuing operations

* Chromadex Corp - qtrly ‍reported net sales of $6.1 million from continuing operations compared to $3.9 million for Q3 of 2016​ Source text: (http://bit.ly/2zpFLpg) Further company coverage:

BRIEF-ChromaDex Q3 loss per share $0.07 from continuing operations

* Q3 sales rose 55 percent to $6.1 million Source text for Eikon: Further company coverage:

BRIEF-Chromadex announces $23 mln private placement of common stock

* Chromadex announces $23 million private placement of common stock

BRIEF-Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 mln

* Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 million - SEC filing Source text: [http://bit.ly/2z2cq3P] Further company coverage:

BRIEF-Chromadex announces top-line results of its second human clinical trial

* Chromadex announces top-line results of its second human clinical trial

Select another date: